Arovella Therapeutics (ASX:ALA) said a second clinical batch of ALA-101, its cell therapy for blood cancers, has been manufactured and released, according to a Wednesday filing on the Australian bourse.

The company added that a third batch, which it expects to release by the end of December, is anticipated to provide enough material to complete the phase 1 trial of 46 patients across five hospital sites.